Neumann B, Shi T, Gan L, Klippert A, Daskalaki M, Stolte-Leeb N, et al. Comprehensive panel of cross-reacting monoclonal antibodies for analysis of different immune cells and their distribution in the common marmoset (Callithrix jacchus). J Med Primatol. 2016;45:139-46 pubmed publisher

Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed publisher

Labani-Motlagh A, Israelsson P, Ottander U, Lundin E, Nagaev I, Nagaeva O, et al. Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity. Tumour Biol. 2016;37:5455-66 pubmed publisher

Djurisic S, Skibsted L, Hviid T. A Phenotypic Analysis of Regulatory T Cells and Uterine NK Cells from First Trimester Pregnancies and Associations with HLA-G. Am J Reprod Immunol. 2015;74:427-44 pubmed publisher

Chen M, Hu P, Ling N, Peng H, Lei Y, Hu H, et al. Enhanced functions of peripheral γδ T cells in chronic hepatitis B infection during interferon α treatment in vivo and in vitro. PLoS ONE. 2015;10:e0120086 pubmed publisher

de Groen R, Boltjes A, Hou J, Liu B, McPhee F, Friborg J, et al. IFN-λ-mediated IL-12 production in macrophages induces IFN-γ production in human NK cells. Eur J Immunol. 2015;45:250-9 pubmed publisher

Cimini E, Agrati C, D'Offizi G, Vlassi C, Casetti R, Sacchi A, et al. Primary and Chronic HIV Infection Differently Modulates Mucosal Vδ1 and Vδ2 T-Cells Differentiation Profile and Effector Functions. PLoS ONE. 2015;10:e0129771 pubmed publisher

Diesenberg K, Beerbaum M, Fink U, Schmieder P, Krauss M. SEPT9 negatively regulates ubiquitin-dependent downregulation of EGFR. J Cell Sci. 2015;128:397-407 pubmed publisher

Wu Z, Frascaroli G, Bayer C, Schmal T, Mertens T. Interleukin-2 from Adaptive T Cells Enhances Natural Killer Cell Activity against Human Cytomegalovirus-Infected Macrophages. J Virol. 2015;89:6435-41 pubmed publisher

Ming Lim C, Stephenson R, Salazar A, Ferris R. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells. Oncoimmunology. 2013;2:e24677 pubmed

Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, et al. Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome. Oncoimmunology. 2013;2:e23080 pubmed